BioPharma Resources

Drug Trial Radar · NCT06452277

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 444 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

444

Planned (sponsor's estimate)

Start

Aug 28, 2024

Primary completion

Oct 28, 2027

Study completion Jun 27, 2029

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer that has spread nearby or to other parts of the body or is unlikely to be controlled with current treatments. HER2 is a protein that helps cells to grow and divide. Sometimes, cancer cells have a damaged HER2 gene. This is called a mutation. This mutation can lead to an abnormal HER2 protein which may cause cancer cells to grow and divide too quickly. The study treatment, sevabertinib, is designed to block the mutated HER2 protein and may help slow or stop the cancer from growing. The main purpose of this study is to find out how well sevabertinib works and how safe it is, compared with standard treatment in participants with advanced NSCLC with a HER2 mutation. The study participants will receive one of the study treatments: * Sevabertinib as a tablet taken by mouth twice a day * Standard approved treatment for this condition given by infusion into a vein every 21 days Participants will continue their assigned treatment for as long as they benefit from it and do not experience severe side effects, or until they or their doctor decide to stop treatment. When a participant assigned to the standard treatment has their cancer gets worse, they may have the opportunity to switch to receive sevabertinib. This switch is called a crossover. Participants who switch to sevabertinib will continue this treatment until their disease gets worse again, they have side effects that are too severe, or they or their doctor decide to stop treatment. During the study, the research team will: * do scans such as CT, PET, MRI, or X-rays to check the cancer * Check the overall health of the participants by performing tests such as blood and urine tests and checking heart health using an electrocardiogram and echocardiogram. * do pregnancy tests when needed * ask how the participants are feeling and whether they have had any adverse events or other health problems An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

Conditions

  • Advanced Non-small Cell Lung Cancer, HER2 Mutation

Interventions

  • SevabertinibDrug

    Tablet, oral

  • PembrolizumabDrug

    Intravenous (IV) infusion

  • CisplatinDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • PemetrexedDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) per RECIST 1.1 as assessed by BICRTime frame: Up to approximately 2 years

Locations

279 sites in 36 countries. Site status is shown where the registry gives one.

  • Patty & George Hoag Cancer Center

    Newport Beach, California · Withdrawn

  • UC San Diego Health - Moores Cancer Center

    San Diego, California · Withdrawn

  • UCSF Bakar Precision Cancer Medicine Building - Thoracic Surgery and Oncology

    San Francisco, California · Recruiting

  • UCLA Health Santa Monica Cancer Care

    Santa Monica, California · Recruiting

  • The Oncology Institute of Hope and Innovation - Fort Lauderdale 17th Street

    Fort Lauderdale, Florida · Recruiting

  • Memorial Cancer Institute at Miramar

    Miramar, Florida · Withdrawn

  • AdventHealth Cancer Institute Orlando

    Orlando, Florida · Not yet recruiting

  • Moffitt Cancer Center - Magnolia Campus

    Tampa, Florida · Withdrawn

  • Piedmont Healthcare - Atlanta

    Atlanta, Georgia · Recruiting

  • John B. Amos Cancer Center

    Columbus, Georgia · Recruiting

  • University of Illinois Hospital - Outpatient Cancer Care Center

    Chicago, Illinois · Recruiting

  • The University of Chicago Medical Center - Hyde Park - Hematology & Oncology

    Chicago, Illinois · Withdrawn

  • UM Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Not yet recruiting

  • UMass Memorial Medical Center - University Campus - Hematology/Oncology

    Worcester, Massachusetts · Withdrawn

  • Profound Research -OMG - TriAtria Cancer Center

    Farmington Hills, Michigan · Withdrawn

  • Profound Research - OMG - Royal Oak Cancer Center

    Royal Oak, Michigan · Withdrawn

  • M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center

    Minneapolis, Minnesota · Withdrawn

  • R.J. Zuckerberg Cancer Center

    New Hyde Park, New York · Withdrawn

  • UC Medical Center - Oncology

    Cincinnati, Ohio · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • Providence Cancer Institute - Franz Clinic

    Portland, Oregon · Withdrawn

  • Providence Oncology and Hematology Care Clinic Westside

    Portland, Oregon · Withdrawn

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • University Hospital Simmons Cancer Center Lung/Head Neck Clinic

    Dallas, Texas · Withdrawn

  • The University of Texas MD Anderson Cancer Center - Texas Medical Center

    Houston, Texas · Recruiting

  • Fundación Cenit para la Investigación en Neurociencias

    Buenos Aires, Argentina · Withdrawn

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Withdrawn

  • Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)

    Buenos Aires, Argentina · Withdrawn

  • Centro Médico Privado CEMAIC

    Córdoba, Argentina · Withdrawn

  • Instituto Argentino de Diagnostico y Tratamiento (IADT)

    TBC, Buenos Aires, Argentina · Withdrawn

  • Centro de Investigaciones Clínicas, Clínica Viedma

    Viedma, Río Negro Province, Argentina · Withdrawn

  • NSW Health - Blacktown Hospital

    Blacktown, New South Wales, Australia · Active not recruiting

  • Concord Repatriation General Hospital - Medical Oncology Clinical Trials Unit

    Concord, New South Wales, Australia · Completed

  • Calvary Mater Hospital Newcastle - Oncology

    Waratah, New South Wales, Australia · Active not recruiting

  • University of the Sunshine Coast

    Buderim, Queensland, Australia · Withdrawn

  • Toowoomba Hospital Oncology Clinical Trials

    Toowoomba, Queensland, Australia · Withdrawn

  • Austin Hospital - Olivia Newton John Cancer Research Institute

    Heidelberg, Victoria, Australia · Active not recruiting

  • Klinik Floridsdorf, Pneumo-onkologische Ambulanz und Tagesklinik

    Vienna, Austria · Active not recruiting

  • Uniklinikum Salzburg, Universitätsklinik für Innere Medizin III

    Vienna, State of Salzburg, Austria · Withdrawn

  • Uniklinikum Salzburg, Universitätsklinik für Pneumologie/ Lungenheilkunde

    Vienna, State of Salzburg, Austria · Withdrawn

Showing 40 of 279 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.